Physician profile
Jay Patel
NPI 1558866855
$757.64
in general payments reported to CMS, 2019-2025
11 companies · $264 in 2025
The $264 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.90 · 2023: $401 · 2024: $80.18 · 2025: $264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $745.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $744.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $262.22 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.83 | 2023-2024 | Jardiance |
| Pfizer INC. | $69.90 | 2024-2025 | |
| Integra Lifesciences Corporation | $68.05 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Paratek Pharmaceuticals, INC. | $47.25 | 2025 | Nuzyra |
| E.R. Squibb & Sons, L.L.C. | $46.50 | 2023 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $45.58 | 2025 | Lifevest |
| Vertex Pharmaceuticals Incorporated | $29.77 | 2024 | |
| Scpharmaceuticals INC. | $22.99 | 2025 | |
| Novo Nordisk INC | $14.65 | 2023 | Rybelsus, Ozempic |
| Boston Scientific Corporation | $12.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.